We provide comprehensive consulting services to lead the preclinical, clinical and business development of therapeutics in oncology, inflammation, CV and related indications with particular focus on targeted small molecule therapeutics such as kinase inhibitors and immunotherapies. Our capabilities encompass the ability to work in a cross-functional manner and leverage external resources to conduct in vitro/in vivo pharmacology studies, toxicology, PK/PD, IND-enabling studies, biomarker/bioassay development and support clinical development strategies using innovative translational medicine methodologies that included the validation of exploratory endpoints. Specialized services included IP evaluation and strategy support, competitive analysis, alliance development/management, licensing opportunity evaluations and support of investor interactions.